Connect your AI

Regenxbio RGNX Other Working Capital

Other Working Capital at other companies

Sarepta Therapeutics, Inc.SRPT

$1.29M+394%

BiogenBIIB

$89M+66.4%

BioMarin PharmaceuticalsBMRN

$5.37M+324%

Ultragenyx PharmaceuticalRARE

-$1M-200%

Solid Biosciences Inc.SLDB

$0-100%

Viridian Therapeutics, Inc.VRDN

-$169K-2,917%

Other financials

Income statement

Revenue$6.4M-92.8%

Gross profit$14.9M+35.7%

Operating income-$83.4M-787%

Net income-$90.1M-1,580%

EPS (diluted)-$1.72-1,533%

Balance sheet

Cash & equivalents$15.2M-88.3%

Total debt$71.1M-11.0%

Total equity$21.1M-92.3%

Total assets$341.9M-30.4%

Cash flow

Operating cash flow-$76.2M-327%

CapEx$1.2M+20.6%

Free cash flow-$77.4M-337%

Valuation

Market cap$529.38M+24.6%

Enterprise value$585.22M+56.3%

P/S6×+3.3×

Profitability

Gross margin59.7%+1.0pp

Operating margin-292.3%-613pp

Net margin-330.2%-588pp

FCF margin-269.2%-364pp

Returns & leverage

Return on equity-196.4%-288pp

Debt / equity3.4×+3.1×

Current ratio2.6×-0.3×

Where this comes from

Reported directly by Regenxbio in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regenxbio's other working capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Regenxbio's other working capital?: Regenxbio (RGNX) reported other working capital of -$19K in Q1 2026.
How has Regenxbio's other working capital changed year-over-year?: Regenxbio's other working capital decreased by 290.0% year-over-year, from $10K to -$19K.
What does other working capital mean?: Net change in working capital items not separately classified — a residual balancing item.